ABCB1 (P-glycoprotein) and the clinical pharmacology of adverse drug reactions

Adverse Drug Reaction Bulletin

Volumn , Issue 263, 2010, Pages 1011-1014

  Ferner, R E ^a,b  

^a CITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; ARIPIPRAZOLE; ATORVASTATIN; AZITHROMYCIN; CALCINEURIN INHIBITOR; CARDIOVASCULAR AGENT; CENTRAL STIMULANT AGENT; CITALOPRAM; CLOXACILLIN; COLCHICINE; DEXTROMETHORPHAN; DIGOXIN; HALOPERIDOL; HYPOCHOLESTEROLEMIC AGENT; LOPERAMIDE; MIRTAZAPINE; MULTIDRUG RESISTANCE PROTEIN 1; PAROXETINE; QUINIDINE; RISPERIDONE; SIMVASTATIN; TACROLIMUS; UNINDEXED DRUG; VENLAFAXINE; VERAPAMIL;

ADVERSE DRUG REACTION; BLOOD BRAIN BARRIER; BLOOD PLACENTA BARRIER; DRUG ABSORPTION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG METABOLISM; DRUG RESPONSE; DRUG TRANSPORT; DRUG TREATMENT FAILURE; FAMILIAL MEDITERRANEAN FEVER; FETOPLACENTAL UNIT; GENE AMPLIFICATION; GENE EXPRESSION; GENE LINKAGE DISEQUILIBRIUM; GENE STRUCTURE; HUMAN; INTESTINE ABSORPTION; KIDNEY TUBULE ABSORPTION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; POINT MUTATION; PROTEIN STRUCTURE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 77956088030     PISSN: 00446394     EISSN: None     Source Type: Journal    
DOI: 10.1097/FAD.0b013e32833ee68a     Document Type: Review

References (45)

1. Franke RM, Sparreboom A. Drug transporters: recent advances and therapeutic applications. Clin Pharmacol Ther 2010;87 (1):3-7.
2. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976;455 (1):152-162.
3. Ueda K, Cornwell MM, Gottesman MM, et al. The mdr1 gene, responsible for multi-drug-resistance, codes for P-glycoprotein. Biochem Biophys Res Commun 1986;141 (3):956-962. (Pubitemid 17006141)
4. MIM *171050.
5. Cropp CD, Yee SW, Giacomini KM. Genetic variation in drug transporters in ethnic populations. Clin Pharmacol Ther 2008;84 (3):412-416.
6. Cascorbi I. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther 2006;112 (2):457-473. (Pubitemid 44486412)
7. Kroetz DL, Pauli-Magnus C, Hodges LM, et al. Pharmacogenetics of Membrane Transporters Investigators sequence diversity and haplotype structure in the human ABCB1(MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003;13 (8):481-494.
8. Dawson RJ, Locher KP. Structure of a bacterial multidrug ABC transporter. Nature 2006;443 (7108):180-185.
9. Murakami S, Nakashima R, Yamashita E, Matsumoto T, Yamaguchi A. Crystal structures of a multidrug transporter reveal a functionally rotating mechanism. Nature 2006;443 (7108):173-179. (Pubitemid 44387601)
10. Becker JP, Depret G, Van Bambeke F, Tulkens PM, Prévost M. Molecular models of human P-glycoprotein in two different catalytic states. BMC Struct Biol 2009;9:3.
11. A primer on the mechanics of P-glycoprotein the multidrug transporter.
12. Ernst R, Kueppers P, Stindt J, Kuchler K, Schmitt L. Multidrug efflux pumps: substrate selection in ATP-binding cassette multidrug efflux pumps-first come, first served? FEBS J 2010;277 (3):540-549.
13. Crowley E, Callaghan R. Multidrug efflux pumps: drug binding-gates or cavity?
14. Urquhart BL, Kim RB. Blood-brain barrier transporters and response to CNS-active drugs. Eur J Clin Pharmacol 2009;65 (11):1063-1070.
15. Keogh JP, Kunta JR. Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein. Eur J Pharm Sci 2006;27 (5):543-554.
16. Uhr M, Tontsch A, Namendorf C, et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 2008;57 (2):203-209.
17. Kirschbaum KM, Henken S, Hiemke C, Schmitt U. Pharmacodynamic consequences of P-glycoprotein-dependent pharmacokinetics of risperidone and haloperidol in mice. Behav. Brain Res 2008;188 (2):298-303.
18. Wang JS, Zhu HJ, Donovan JL, et al. Aripiprazole brain concentration is altered in P-glycoprotein deficient mice. Schizophr Res 2009;110 (1-3):90-94.
19. Kato M, Fukuda T, Serretti A, et al. ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008;32 (2):398-404.
20. Campa D, Gioia A, Tomei A, Poli P, Barale R. Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther 2008;83 (4):559-566. (Pubitemid 351417058)
21. Coulbault L, Beaussier M, Verstuyft C, et al. Environmental and genetic factors associated with morphine response in the postoperative period. Clin Pharmacol Ther 2006;79 (4):316-324.
22. Aquilante CL, Letrent SP, Pollack GM, Brouwer KL. Increased brain P-glycoprotein in morphine tolerant rats. Life Sci 2000;66 (4):PL47-PL51.
23. Coller JK, Barratt DT, Dahlen K, Loennechen MH, Somogyi AA. ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Clin Pharmacol Ther 2006;80:682-690.
24. Crettol S, Déglon JJ, Besson J, et al. No influence of ABCB1 haplotypes on methadone dosage requirement. Clin Pharmacol Ther 2008;83 (5):668-669. (Pubitemid 351556009)
25. Coller JK, Barratt DT, Somogyi AA. Response to "No Influence of ABCB1 Genotypes on Methadone Dosage Requirement". Clin Pharmacol Ther 2008;83 (5):669-670. (Pubitemid 351556017)
26. Urquhart BL, Kim RB. Blood-brain barrier transporters and response to CNS-active drugs. Eur J Clin Pharmacol 2009;65 (11):1063-1070.
27. Schinkel AH, Wagenaar E, Mol CA, van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996;97 (11):2517-2524.
28. Sissung TM, Mross K, Steinberg SM, Behringer D, Figg WD, Sparreboom A, Mielke S. Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur J Cancer 2006;42 (17):2893-2896. Epub 2006 Sep 6. (Pubitemid 44755257)
29. Takano M, Yumoto R, Murakami T. Expression and function of efflux drug transporters in the intestine. Pharmacol Ther 2006;109 (1-2):137-161. (Pubitemid 41740818)
30. Greiner B, Eichelbaum M, Fritz P, et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999;104 (2):147-153.
31. Niemi M. Transporter pharmacogenetics and statin toxicity. Clin Pharmacol Ther 2010;87 (1):130-133.
32. The SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy - a genomewide study. N Engl J Med 2008;359:789-799.
33. He XJ, Zhao LM, Qiu F, Sun YX, Li-Ling J. Influence of ABCB1 gene polymorphisms on the pharmacokinetics of azithromycin among healthy Chinese Han ethnic subjects. Pharmacol Rep 2009;61 (5):843-850.
34. Yin OQ, Tomlinson B, Chow MS. Effect of multidrug resistance gene-1 (ABCB1) polymorphisms on the single-dose pharmacokinetics of cloxacillin in healthy adult Chinese men. Clin Ther 2009;31:999-1006.
35. Mendes J, Martinho A, Simoes O, Mota A, Breitenfeld L, Pais L. Genetic polymorphisms in CYP3A5 and MDR1 genes and their correlations with plasma levels of tacrolimus and cyclosporine in renal transplant recipients. Transplant Proc 2009;41 (3):840-842.
36. Di Marco MP, Edwards DJ, Wainer IW, Ducharme MP. The effect of grapefruit juice and seville orange juice on the pharmacokinetics of dextromethorphan: the role of gut CYP3A and P-glycoprotein. Life Sci 2002;71 (10):1149-1160.
37. Fromm MF, Kim RB, Stein CM, Wilkinson GR, Roden DM. Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 1999;99 (4):552-557.
38. Aylin Arici M, Kilinc E, Demir O, Ates M, Yesilyurt A, Gelal A. Interactions between verapamil and digoxin in langendorff-perfused rat hearts: the role of inhibition of P-glycoprotein in the heart. Basic Clin Pharmacol Toxicol. 2010 Apr 20. [Epub ahead of print].
39. Liptrott NJ, Penny M, Bray PG, et al. The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC. Br J Pharmacol 2009;156 (3):497-508.
40. Tufan A, Babaoglu MO, Akdogan A, et al. Association of drug transporter gene ABCB1 (MDR1) 3435C to T polymorphism with colchicine response in familial Mediterranean fever. J Rheumatol 2007;34 (7):1540-1544.
41. Bohanec Grabar P, Logar D, Lestan B, Dolzan V. Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolism. Eur J Clin Pharmacol 2008;64 (11):1057-1068.
42. Vähäkangas K, Myllynen P. Drug transporters in the human blood-placental barrier. Br J Pharmacol 2009;158 (3):665-678.
43. Nanovskaya T, Nekhayeva I, Karunaratne N, Audus K, Hankins GD, Ahmed MS. Role of P-glycoprotein in transplacental transfer of methadone. Biochem Pharmacol 2005;69 (12):1869-1878. (Pubitemid 40780085)
44. Ferner RE, Aronson JK. EIDOS: A Mechanistic Classification of Adverse Drug Effects. Drug Safety 2010;33 (1):15-23.
45. DuBuske LM. The role of P-glycoprotein and organic anion-transporting polypeptides in drug interactions. Drug Saf 2005;28 (9):789-801.